J-code: Drugs administered other than oral method; chemotherapy drugs Drugs administered other than oral method; chemotherapy drugs
1,255 codes
Billing context
J-codes are permanent national codes for drugs and biologicals — most often clinician-administered (buy-and-bill) products paid under Medicare Part B — plus certain immunosuppressive, inhalation (via DME), and oral anticancer/antiemetic drugs. Units are reported in multiples of the dosage in the code descriptor.
| Code | Long descriptor | Payment limit (Q4 2026) | Added | Status |
|---|---|---|---|---|
| J9177 | Injection, enfortumab vedotin-ejfv, 0.25 mg | $36.535per 0.25 MG | Jul 1, 2020 | Active |
| J9178 | Injection, epirubicin hcl, 2 mg | $1.868per 2 MG | Jan 1, 2004 | Active |
| J9179 | Injection, eribulin mesylate, 0.1 mg | $63.972per 0.1 MG | Jan 1, 2012 | Active |
| J9181 | Injection, etoposide, 10 mg | — | Jan 1, 1987 | Ended Sep 30, 2026 |
| J9183 | Gemcitabine intravesical system, 225 mg | $73,054.053per 225 MG | Apr 1, 2026 | Active |
| J9184 | Injection, gemcitabine hydrochloride (avyxa), 200 mg | $403.465per 200 MG | Jan 1, 2026 | Active |
| J9185 | Injection, fludarabine phosphate, 50 mg | $177.924per 50 MG | Jan 1, 1994 | Active |
| J9186 | Injection, etoposide (avyxa), 1 mg | $4.240per 1 MG | Oct 1, 2026 | Active |
| J9187 | Injection, etoposide, 1 mg | $0.094per 1 MG | Oct 1, 2026 | Active |
| J9190 | Injection, fluorouracil, 500 mg | — | Jan 1, 1984 | Ended Sep 30, 2026 |
| J9191 | Injection, fluorouracil (avyxa), 10 mg | $14.840per 10 MG | Oct 1, 2026 | Active |
| J9192 | Injection, fluorouracil, 10 mg | $0.039per 10 MG | Oct 1, 2026 | Active |
| J9196 | Injection, gemcitabine hydrochloride (accord), not therapeutically equivalent to j9201, 200 mg | — | Apr 1, 2023 | Active |
| J9198 | Injection, gemcitabine hydrochloride, (infugem), 100 mg | — | Jul 1, 2020 | Active |
| J9199 | Injection, gemcitabine hydrochloride (infugem), 200 mg | — | Jan 1, 2020 | Ended Jun 30, 2020 |
| J9200 | Injection, floxuridine, 500 mg | $4,389.848per 500 MG | Jan 1, 1984 | Active |
| J9201 | Injection, gemcitabine hydrochloride, not otherwise specified, 200 mgNOC / NOS | $2.734per 200 MG | Jan 1, 1998 | Active |
| J9202 | Goserelin acetate implant, per 3.6 mg | — | Jan 1, 1991 | Active |
| J9203 | Injection, gemtuzumab ozogamicin, 0.1 mg | $247.370per 0.1 MG | Jan 1, 2018 | Active |
| J9204 | Injection, mogamulizumab-kpkc, 1 mg | $258.536per 1 MG | Oct 1, 2019 | Active |
| J9205 | Injection, irinotecan liposome, 1 mg | $66.856per 1 MG | Jan 1, 2017 | Active |
| J9206 | Injection, irinotecan, 20 mg | $1.569per 20 MG | Jan 1, 1998 | Active |
| J9207 | Injection, ixabepilone, 1 mg | $139.498per 1 MG | Jan 1, 2009 | Active |
| J9208 | Injection, ifosfamide, 1 gram | $27.905per 1 GM | Jan 1, 1990 | Active |
| J9209 | Injection, mesna, 200 mg | $1.203per 200 MG | Jan 1, 1990 | Active |
| J9210 | Injection, emapalumab-lzsg, 1 mg | $391.861per 1 MG | Oct 1, 2019 | Active |
| J9211 | Injection, idarubicin hydrochloride, 5 mg | $33.394per 5 MG | Jan 1, 1993 | Active |
| J9212 | Injection, interferon alfacon-1, recombinant, 1 microgram | — | Jan 1, 1999 | Ended Dec 31, 2025 |
| J9213 | Injection, interferon, alfa-2a, recombinant, 3 million units | — | Jan 1, 1993 | Active |
| J9214 | Injection, interferon, alfa-2b, recombinant, 1 million units | — | Jan 1, 1993 | Active |
| J9215 | Injection, interferon, alfa-n3, (human leukocyte derived), 250,000 iu | — | Jan 1, 1993 | Active |
| J9216 | Injection, interferon, gamma 1-b, 3 million units | — | Jan 1, 1993 | Active |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | $188.849per 7.5 MG | Jan 1, 1991 | Active |
| J9218 | Leuprolide acetate, per 1 mg | — | Jan 1, 1990 | Active |
| J9219 | Leuprolide acetate implant, 65 mg | — | Jan 1, 2001 | Active |
| J9220 | Injection, indigotindisulfonate sodium, 1 mg | — | Jul 1, 2025 | Active |
| J9223 | Injection, lurbinectedin, 0.1 mg | $215.722per 0.1 MG | Jan 1, 2021 | Active |
| J9225 | Histrelin implant (vantas), 50 mg | — | Jan 1, 2006 | Active |
| J9226 | Histrelin implant (supprelin la), 50 mg | $37,837.548per 50 MG | Jan 1, 2008 | Active |
| J9227 | Injection, isatuximab-irfc, 10 mg | $89.812per 10 MG | Oct 1, 2020 | Active |
| J9228 | Injection, ipilimumab, 1 mg | $190.433per 1 MG | Jan 1, 2012 | Active |
| J9229 | Injection, inotuzumab ozogamicin, 0.1 mg | $2,873.103per 0.1 MG | Jan 1, 2019 | Active |
| J9230 | Injection, mechlorethamine hydrochloride, (nitrogen mustard), 10 mg | — | Jan 1, 1986 | Active |
| J9232 | Injection, docetaxel (hospira), not therapeutically equivalent to j9171, 1 mg | $0.513per 1 MG | Jul 1, 2026 | Active |
| J9245 | Injection, melphalan hydrochloride, not otherwise specified, 50 mgNOC / NOS | $90.032per 50 MG | Jan 1, 1995 | Active |
| J9246 | Injection, melphalan (evomela), 1 mg | $18.569per 1 MG | Jul 1, 2020 | Active |
| J9247 | Injection, melphalan flufenamide, 1mg | — | Oct 1, 2021 | Ended Mar 31, 2025 |
| J9248 | Injection, melphalan (hepzato), 1 mg | $797.415per 1 MG | Apr 1, 2024 | Active |
| J9249 | Injection, melphalan (apotex), 1 mg | — | Apr 1, 2024 | Active |
| J9250 | Methotrexate sodium, 5 mg | — | Jan 1, 1994 | Ended Mar 31, 2024 |
| J9255 | Injection, methotrexate (accord), not therapeutically equivalent to j9260, 50 mg | — | Jan 1, 2024 | Active |
| J9256 | Injection, nipocalimab-aahu, 3 mg | $32.321per 3 MG | Jan 1, 2026 | Active |
| J9258 | Injection, paclitaxel protein-bound particles (teva), not therapeutically equivalent to j9264, 1 mg | — | Jan 1, 2024 | Ended Sep 30, 2024 |
| J9259 | Injection, paclitaxel protein-bound particles (american regent), not therapeutically equivalent to j9264, 1 mg | — | Jul 1, 2023 | Ended Dec 31, 2024 |
| J9260 | Injection, methotrexate sodium, 50 mg | $2.909per 50 MG | Jan 1, 1984 | Active |
| J9261 | Injection, nelarabine, 50 mg | $40.872per 50 MG | Jan 1, 2007 | Active |
| J9262 | Injection, omacetaxine mepesuccinate, 0.01 mg | — | Jan 1, 2014 | Active |
| J9263 | Injection, oxaliplatin, 0.5 mg | $0.087per 0.5 MG | Jan 1, 2004 | Active |
| J9264 | Injection, paclitaxel protein-bound particles, 1 mg | $3.640per 1 MG | Jan 1, 2006 | Active |
| J9265 | Injection, paclitaxel, 30 mg | — | Jan 1, 1994 | Ended Dec 31, 2014 |
| J9266 | Injection, pegaspargase, per single dose vial | $29,845.265per 1 EA | Jan 1, 1996 | Active |
| J9267 | Injection, paclitaxel, 1 mg | $0.108per 1 MG | Jan 1, 2015 | Active |
| J9268 | Injection, pentostatin, 10 mg | $2,612.893per 10 MG | Jan 1, 1994 | Active |
| J9269 | Injection, tagraxofusp-erzs, 10 micrograms | $357.292per 10 MCG | Oct 1, 2019 | Active |
| J9270 | Injection, plicamycin, 2.5 mg | — | Jan 1, 1984 | Ended Dec 31, 2025 |
| J9271 | Injection, pembrolizumab, 1 mg | $62.253per 1 MG | Jan 1, 2016 | Active |
| J9272 | Injection, dostarlimab-gxly, 10 mg | $250.548per 10 MG | Jan 1, 2022 | Active |
| J9273 | Injection, tisotumab vedotin-tftv, 1 mg | $196.121per 1 MG | Apr 1, 2022 | Active |
| J9274 | Injection, tebentafusp-tebn, 1 microgram | $228.006per 1 MCG | Oct 1, 2022 | Active |
| J9275 | Injection, cosibelimab-ipdl, 2 mg | $21.989per 2 MG | Jul 1, 2025 | Active |
| J9276 | Injection, zanidatamab-hrii, 2 mg | $25.734per 2 MG | Jul 1, 2025 | Active |
| J9277 | Injection, pembrolizumab, 1 mg and berahyaluronidase alfa-pmph | $32.307per 1 MG | Apr 1, 2026 | Active |
| J9278 | Injection, carboplatin (avyxa), 1 mg | $5.226per 1 MG | Apr 1, 2026 | Active |
| J9280 | Injection, mitomycin, 5 mg | $34.838per 5 MG | Jan 1, 1986 | Active |
| J9281 | Mitomycin pyelocalyceal instillation, 1 mg | $329.071per 1 MG | Jan 1, 2021 | Active |
| J9282 | Mitomycin, intravesical instillation, 1 mg | $272.918per 1 MG | Jan 1, 2026 | Active |
| J9285 | Injection, olaratumab, 10 mg | — | Jan 1, 2018 | Active |
| J9286 | Injection, glofitamab-gxbm, 2.5 mg | $2,859.117per 2.5 MG | Jan 1, 2024 | Active |
| J9289 | Injection, nivolumab, 2 mg and hyaluronidase-nvhy | $27.989per 2 MG | Jul 1, 2025 | Active |
| J9292 | Injection, pemetrexed dipotassium, 10 mg | $76.690per 10 MG | Jan 1, 2025 | Active |
| J9293 | Injection, mitoxantrone hydrochloride, per 5 mg | $19.418per 5 MG | Jan 1, 1990 | Active |
| J9294 | Injection, pemetrexed (hospira), not therapeutically equivalent to j9305, 10 mg | $3.678per 10 MG | Apr 1, 2023 | Active |
| J9295 | Injection, necitumumab, 1 mg | — | Jan 1, 2017 | Active |
| J9296 | Injection, pemetrexed (accord), not therapeutically equivalent to j9305, 10 mg | — | Apr 1, 2023 | Active |
| J9297 | Injection, pemetrexed (sandoz), not therapeutically equivalent to j9305, 10 mg | $4.879per 10 MG | Apr 1, 2023 | Active |
| J9298 | Injection, nivolumab and relatlimab-rmbw, 3 mg/1 mg | $205.442per 3 mg/1 mg | Oct 1, 2022 | Active |
| J9299 | Injection, nivolumab, 1 mg | $34.191per 1 MG | Jan 1, 2016 | Active |
| J9300 | Injection, gemtuzumab ozogamicin, 5 mg | — | Jan 1, 2002 | Ended Dec 31, 2017 |
| J9301 | Injection, obinutuzumab, 10 mg | $85.039per 10 MG | Jan 1, 2015 | Active |
| J9302 | Injection, ofatumumab, 10 mg | — | Jan 1, 2011 | Active |
| J9303 | Injection, panitumumab, 10 mg | $183.275per 10 MG | Jan 1, 2008 | Active |
| J9304 | Injection, pemetrexed (pemfexy), 10 mg | $92.505per 10 MG | Oct 1, 2020 | Active |
| J9305 | Injection, pemetrexed, not otherwise specified, 10 mgNOC / NOS | $1.230per 10 MG | Jan 1, 2005 | Active |
| J9306 | Injection, pertuzumab, 1 mg | $17.269per 1 MG | Jan 1, 2014 | Active |
| J9307 | Injection, pralatrexate, 1 mg | $384.572per 1 MG | Jan 1, 2011 | Active |
| J9308 | Injection, ramucirumab, 5 mg | $76.398per 5 MG | Jan 1, 2016 | Active |
| J9309 | Injection, polatuzumab vedotin-piiq, 1 mg | $144.103per 1 MG | Jan 1, 2020 | Active |
| J9310 | Injection, rituximab, 100 mg | — | Jan 1, 1999 | Ended Dec 31, 2018 |
| J9311 | Injection, rituximab 10 mg and hyaluronidase | $36.265per 10 mg | Jan 1, 2019 | Active |
| J9312 | Injection, rituximab, 10 mg | $72.094per 10 MG | Jan 1, 2019 | Active |